Featuring market attractiveness scoring, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, deeper supply chain intelligence, emerging startup tracking, and granular product-level insights, The Business Research Company’s 2026 market reports are built to deliver research that is both more actionable and more strategically valuable.
Hematologic Malignancies Testing Market Set To Climb From $4.06 Billion In 2026 To $6.68 Billion By 2030
The hematologic malignancies testing market has seen a rapid increase in size recently. Projections indicate it will expand from $3.58 billion in 2025 to $4.06 billion by 2026, demonstrating a compound annual growth rate (CAGR) of 13.4%. Historically, this growth has been driven by several factors, including an increasing incidence of hematologic cancers, broader adoption of molecular diagnostics, the expansion of diagnostic laboratory networks, the escalating use of cbc and flow cytometry, and enhanced access to oncology testing services.
The hematologic malignancies testing market is projected to experience substantial expansion over the coming years. This market is anticipated to reach $6.68 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 13.2%. The driving forces behind this growth during the forecast period include a heightened demand for precision oncology diagnostics, the increasing incorporation of AI-based data interpretation, the broadening scope of companion diagnostics, a greater uptake of MRD monitoring, and increased investments in sophisticated diagnostic technologies. Key trends expected within the forecast timeframe encompass the expanding adoption of NGS-based diagnostic testing, a surge in the application of flow cytometry for MRD detection, the growing convergence of molecular and genetic assays, the widening availability of personalized diagnostic profiling, and an intensified emphasis on early and precise subtyping.
Get A Free Sample Report With In-Depth Market Insights:
Hematologic Malignancies Testing Market Growth Factors: What’s Supporting Expansion?
The increasing incidence of cancer diagnoses is anticipated to stimulate the expansion of the hematologic malignancies testing market in the future. Cancer diagnoses involve determining the existence, category, and progression of cancer in individuals through various medical examinations and assessments, including imaging, lab tests, and biopsies. This surge in cancer diagnoses stems from enhanced availability of screening initiatives and increased public understanding, leading to earlier detection. Hematologic malignancies testing supports cancer diagnoses by facilitating prompt discovery, precise categorization, and ongoing surveillance of blood-related cancers, which in turn informs specific treatment strategies and enhances patient outcomes. For instance, the American Cancer Society, an US-based nonprofit organization, projects that in 2024, over 2 million new cancer cases will be diagnosed in the US, representing a 4% increase from previous years. Consequently, the growing incidence of cancer diagnoses fuels expansion within the hematologic malignancies testing market.
Hematologic Malignancies Testing Market Segments: Where Is Growth Concentrated?
The hematologic malignancies testing market covered in this report is segmented –
1) By Test Type: Complete Blood Count (CBC), Flow Cytometry, Molecular Testing, Genetic Testing, Others Test Type
2) By Product: Kits, Services
3) By Technology: Polymerase Chain Reaction (PCR), Next-Generation Sequencing (NGS), Immunohisto Chemistry (IHC), Cytogenetics, Others Technology
4) By Therapeutic Indication: Leukemia, Lymphoma, Multiple Myeloma, Myeloproliferative Neoplasms, Others Therapeutic Indication
5) By End User: Hospitals, Diagnostic Labs, Academic and Research Institutions, Others End Users
Subsegments:
1) By Complete Blood Count (CBC): Hemoglobin Testing, Hematocrit Measurement, White Blood Cell Count, Red Blood Cell Count, Platelet Count, Mean Corpuscular Volume (MCV), Mean Corpuscular Hemoglobin (MCH)
2) By Flow Cytometry: Immunophenotyping, Cell Cycle Analysis, Apoptosis Detection, Minimal Residual Disease (MRD) Testing, DNA Content Analysis
3) By Molecular Testing: Polymerase Chain Reaction (PCR), Next-Generation Sequencing (NGS), Reverse Transcriptase-PCR (RT-PCR), Fluorescence In Situ Hybridization (FISH), Microarray Analysis
4) By Genetic Testing: Germline Mutation Testing, Somatic Mutation Testing, Cytogenetic Testing, Chromosomal Aberration Detection, Single Nucleotide Polymorphism (SNP) Analysis
5) By Others Test Type: Bone Marrow Biopsy, Immunohistochemistry (IHC), Enzyme Assays, Serum Protein Electrophoresis (SPEP), Imaging Tests
Hematologic Malignancies Testing Market Trends Shaping Long-Term Demand
Major companies in the hematologic malignancies testing market are focusing on the development of innovative diagnostic approaches, such as rapid molecular profiling, to supply healthcare providers with precise and timely diagnostic tools that enhance early detection, treatment planning, and monitoring of blood cancers. Rapid molecular profiling is a diagnostic technique that analyzes a patient’s genetic makeup to identify mutations and variations, allowing for faster and more personalized treatment decisions. For instance, in November 2023, Roswell Park Comprehensive Cancer Center, a US-based comprehensive cancer center, launched PanHeme, a next-generation gene sequencing tool designed to diagnose hematologic cancers such as leukemia, lymphoma, and multiple myeloma more accurately and quickly. The test identifies mutations in hundreds of genes in under 72 hours, significantly improving the speed and precision of diagnosis and ultimately guiding more personalized treatment decisions for patients.
Hematologic Malignancies Testing Market Key Participants And Competitive Landscape
Major companies operating in the hematologic malignancies testing market are Abbott Laboratories, F. Hoffmann-La Roche Ltd, Siemens Healthineers AG, Becton Dickinson and Company, Bio-Rad Laboratories Inc., Agilent Technologies Inc., Illumina Inc., Thermo Fisher Scientific Inc., Danaher Corporation, Sysmex Corporation, QIAGEN N.V., PerkinElmer Inc., Adaptive Biotechnologies Corporation, Invivoscribe Inc., ArcherDx Inc., Guardant Health Inc., Sophia Genetics SA, Natera Inc., Roche Diagnostics International AG, Laboratory Corporation of America Holdings
View The Full Hematologic Malignancies Testing Market Report:
Hematologic Malignancies Testing Market Global Footprint: Which Region Leads The Market?
North America was the largest region in the hematologic malignancies testing market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the hematologic malignancies testing market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Reach Out To Our Team:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model









